Steadybase.

Obsidian Therapeutics, Inc.

Website Investor relations LinkedIn
  • OBX · Nasdaq
  • Pharmaceutical Preparations
  • Cambridge, MA
  • CIK 0002130606

Updated from SEC filings through

Top things to know

Next earningsFebruary 21, 2027Estimated from past filings
Latest 8-KResults of operations and financial conditionFiled November 12, 2026

Executives

Obsidian Therapeutics, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Cambridge, MA. It trades as OBX on Nasdaq. Madan Jagasia is Chief Executive Officer.

Five-year financials

We have no annual financials for this company yet.

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Madan Jagasia Madan Jagasia
Biotechnology Executive
Chief Executive Officer Form 4, August 5, 2026
Julie B. Feder
CFO
Chief Financial Officer Form 3, August 3, 2026
Parameswaran Hari
Chief Medical Officer , Obsidian Therapeutics
Chief Medical Officer Form 3, August 3, 2026

What Obsidian Therapeutics, Inc. does

Obsidian Therapeutics is using its proprietary cytoDRiVE® platform to harness the power of proteins to engineer precision medicines.

Company website description, 10-K for the year ending November 7, 2026

Shares and governance

Shares outstanding 61.8 million (as of November 9, 2026) 10-Q, November 12, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 12, 2026

Recent 8-K events

  • 8-K filed 2026-11-12
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2026-08-03
    • Item 1.01 Entry into a material definitive agreement
    • Item 2.01 Completion of acquisition or disposition of assets
    • Item 2.02 Results of operations and financial condition (earnings release)
    • Item 3.02 Unregistered sales of equity securities
    • Item 3.03 Material modification to rights of security holders
    • Item 4.01 Changes in registrant's certifying accountant
    • Item 5.01 Changes in control of registrant
    • Item 5.02 Departure or appointment of directors or officers; compensation
    • Item 5.03 Amendments to articles or bylaws; change in fiscal year
    • Item 7.01 Regulation FD disclosure

Frequently asked questions about Obsidian Therapeutics, Inc.

What does Obsidian Therapeutics, Inc. do?
In its own words, from Item 1 of its 10-K: "Obsidian Therapeutics is using its proprietary cytoDRiVE® platform to harness the power of proteins to engineer precision medicines."
Who is the CEO of Obsidian Therapeutics, Inc.?
Madan Jagasia, Chief Executive Officer, as named in a 4 filed August 5, 2026.
Who is the CFO of Obsidian Therapeutics, Inc.?
Julie B. Feder, Chief Financial Officer, as named in a 3 filed August 3, 2026.
Where is Obsidian Therapeutics, Inc. headquartered?
Cambridge, MA.
What is Obsidian Therapeutics, Inc.'s stock ticker?
OBX on Nasdaq.
What industry is Obsidian Therapeutics, Inc. in?
Pharmaceutical Preparations, SIC code 2834.
What is Obsidian Therapeutics, Inc.'s website?
obsidiantx.com. Investor relations: https://obsidiantx.com/investors-media/.
When does Obsidian Therapeutics, Inc. report earnings next?
February 21, 2027. This is an estimate from past filing dates, not a confirmed date.
Is Obsidian Therapeutics, Inc. a public company?
Yes. Obsidian Therapeutics, Inc. files with the SEC under CIK 0002130606 and trades as OBX.
How many shares of Obsidian Therapeutics, Inc. are outstanding?
61.8 million shares as of November 9, 2026, from its 10-Q filed November 12, 2026.
How many business segments does Obsidian Therapeutics, Inc. report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 12, 2026.